Get the Stockscreener App
20.04
7.34%
1.37
Pre-market:
20.77
0.73
+3.64%
Biodesix Inc stock is traded at $20.04, with a volume of 244.93K.
It is up +7.34% in the last 24 hours and up +34.23% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
See More
Previous Close:
$18.67
Open:
$19.84
24h Volume:
244.93K
Relative Volume:
3.59
Market Cap:
$207.53M
Revenue:
$88.50M
Net Income/Loss:
$-35.27M
P/E Ratio:
-6.0812
EPS:
-3.2954
Net Cash Flow:
$-23.70M
1W Performance:
+19.21%
1M Performance:
+34.23%
6M Performance:
+193.84%
1Y Performance:
+271.25%
1-Day Range:
$19.03
$22.22
1-Week Range:
$16.51
$22.22
52-Week Range:
$5.006
$22.22
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
20.04 | 193.34M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
505.75 | 182.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.21 | 133.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
554.94 | 43.32B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.51 | 37.18B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
260.74 | 37.23B | 2.50B | -226.32M | 71.51M | -1.6412 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
BDSX Initiated Coverage by Roth Capital -- Price Target Set at $32 - GuruFocus
Roth Capital Initiates Biodesix at Buy With $32 Price Target - marketscreener.com
Biodesix (BDSX) Coverage Initiated with Positive Outlook - GuruFocus
Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Are medical stocks lagging Biodesix (BDSX) this year? - MSN
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains? - Yahoo Finance
BDSX News | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Soleus discloses 525,241-share (5.1%) stake in Biodesix (BDSX) - Stock Titan
Canaccord raises Biodesix stock price target to $27 on growth outlook By Investing.com - Investing.com Australia
Canaccord raises Biodesix stock price target to $27 on growth outlook - Investing.com UK
Biodesix Inc (BDSX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biodesix Inc (BDSX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biodesix Inc (BDSX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biodesix Inc (BDSX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biodesix Inc (BDSX) Institutional Confidence - TradingKey
BDSX Technical Analysis & Stock Price Forecast - Intellectia AI
Biodesix Inc (BDSX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biodesix Inc (BDSX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biodesix Inc (BDSX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BDSX Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Yahoo Finance
HC Wainwright Initiates Biodesix at Buy With $26 Price Target - marketscreener.com
Biodesix, Inc. (BDSX) reports Q1 loss, tops revenue estimates - MSN
BDSX Q1 2026 Earnings: EPS Beat on Lower-Than-Expected Loss; Stock Dips SlightlyLow Growth Earnings - newsline.com
BDSX Q1 2026 Earnings: EPS Surpasses Estimates Despite Net Loss, Stock Ticks DownEarnings Turnaround - newsline.com
Biodesix (BDSX) Tests Resistance After Modest Gain Amid Sector VolatilityVWAP Deviation - newsline.com
Biodesix Inc. (BDSX) Shows Resilience: Shares Gain 2.08% Amid Sector InterestAccumulation Line - newsline.com
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity - sharewise.com
Biodesix Q1 2026 Earnings: EPS Surprise Beats Estimates by 27.5% Amid Revenue Disclosure GapHigh Growth Earnings - newsline.com
[EFFECT] BIODESIX INC SEC Filing - Stock Titan
Biodesix Inc. (BDSX) Climbs 2% as Stock Tests Key Resistance Near $17.14Iron Condor Alert - newsline.com
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodesix (NASDAQ: BDSX) registers resale of 375,000 shares - Stock Titan
Biodesix (BDSX) Gains 1.43% as Shares Test Resistance Near $17New Highs New Lows - The Legal Advocate
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
BDSX Q1 2026 Earnings: EPS Beats Estimates by 27.54% Amid Cost DisciplineEarnings Cycle Report - newsline.com
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade - Zacks Investment Research
Biodesix Inc. (BDSX) Q1 2026 Earnings: Strong EPS Beat Overshadowed by Negative Stock ReactionFinal Results - newsline.com
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions - Insider Monkey
Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale - Stock Titan
Biodesix shareholders elect directors and approve executive compensation By Investing.com - Investing.com South Africa
Biodesix to Participate in Upcoming Investor Conferences - The Manila Times
Biodesix meets investors in Minneapolis, Chicago and Dana Point - Stock Titan
Biodesix shareholders elect directors and approve executive compensation - Investing.com India
Biodesix Shareholders Approve Directors and Governance Measures - TipRanks
Biodesix (NASDAQ: BDSX) holders back directors, pay and KPMG auditor - Stock Titan
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):